Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer

NCT03799835 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03799835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03799835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 17, 2019
Completion date
October 31, 2028
Enrollment
517 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer